Back to top
more

XOMA (XOMA)

(Real Time Quote from BATS)

$25.31 USD

25.31
1,276

-1.19 (-4.49%)

Updated Apr 30, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XOMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

XOMA Corporation [XOMA]

Reports for Purchase

Showing records 41 - 60 ( 328 total )

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 41

01/19/2021

Company Report

Pages: 6

Expecting Strong Partner Data Catalysts and Continued Shopping in 2021; Target Increased to $56

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 42

11/25/2020

Company Report

Pages: 8

Q3: NIS793 Triggers $25M Milestone; Multiple Value-Driving Catalysts in 2021

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 43

11/04/2020

Company Report

Pages: 6

Portfolio Continues to Grow; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 44

10/28/2020

Company Report

Pages: 6

Start a Study, Cash a Big Check; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 45

08/25/2020

Company Report

Pages: 8

Q2 Financials; Royalty Portfolio Coming into Focus in 2021

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 46

08/13/2020

Industry Report

Pages: 18

PacGrow Healthcare Conference: Day 1 - 2 Recap

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 47

05/06/2020

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 48

05/05/2020

Company Report

Pages: 6

1Q20 Results; Steady as She Goes Toward More Deals

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 49

05/05/2020

Company Report

Pages: 6

Q1 Financials; Brief COVID-19 Update

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 50

03/23/2020

Company Report

Pages: 17

Active PoC Assets, Current Phase .2 Trials - Q4/FY19 Results

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 51

03/10/2020

Company Report

Pages: 7

2019 Results; Asset Base and Opportunities Continue to Grow

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 52

03/09/2020

Company Report

Pages: 6

Differentiated IL-2 Program Finds First Potential Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 53

12/06/2019

Company Report

Pages: 8

XOMA Partnered Assets Featured Prominently During Novartis R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 54

11/06/2019

Company Report

Pages: 7

Q3 Financials and Portfolio Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 55

11/05/2019

Company Report

Pages: 6

3Q19 Results; Visibility Continues to Increase on Partnered Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 56

09/27/2019

Company Report

Pages: 7

Assets Continue to Grow in Numbers as New Business Model Is Validated Again; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 57

08/13/2019

Company Report

Pages: 6

Expanded Portfolio of Milestone and Royalty Bearing Assets

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 58

08/07/2019

Company Report

Pages: 7

Q2 Financials and Partner Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 59

08/06/2019

Company Report

Pages: 7

2Q19 Results; Shopping Continues as Partners Advance Pipelines; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 60

08/01/2019

Company Report

Pages: 6

Partner Program Updates - Milestone Payment

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party